Running Late: FDA Review Timelines Lengthen For New Product Applications
This article was originally published in RPM Report
FDA is missing more new drug review deadlines: at least seven in the first eight months of this year. The experiences of those delayed applications indicate some interesting ways to interpret what it means when a user fee date comes and goes without an FDA decision. One clear observation: the longer a sponsor has to wait after the user fee deadline, the worse the likely result.
You may also be interested in...
Drug sponsors are eager to use FDA’s new “breakthrough” therapy development pathway, and the agency is granting designations at a much faster rate than originally expected. But the “all hands on deck” approach required by FDA officials for breakthrough is resource-intensive at a time when the budget sequestration is preventing the agency from accessing all its available user fee funding. Is the popular program at risk?
The Victoza approval took longer than Novo hoped. But the review time looks like nothing compared to the post-marketing monitoring the company will be required to do.
The last thing anyone in the biopharma sector needs is a less predictable drug review process, but there is no denying that the new drug safety law has added another level of uncertainty to the regulatory affairs process. The only thing worse is the fear that some in industry know more than others about the new rules of the road.